Analysts Set Capricor Therapeutics, Inc. (NASDAQ:CAPR) PT at $46.09

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $46.0909.

Several brokerages have recently issued reports on CAPR. Piper Sandler reissued an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. B. Riley Financial upped their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. iA Financial set a $48.00 target price on Capricor Therapeutics in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 29th. Finally, Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th.

Institutional Trading of Capricor Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics in the third quarter valued at about $28,000. Parkside Financial Bank & Trust bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $36,000. Russell Investments Group Ltd. raised its position in shares of Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares in the last quarter. ACT Capital Management LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth $43,000. Finally, GoalVest Advisory LLC bought a new stake in Capricor Therapeutics during the fourth quarter valued at $59,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 3.5%

NASDAQ:CAPR opened at $28.90 on Friday. The company has a market capitalization of $1.66 billion, a P/E ratio of -12.79 and a beta of 0.37. The firm has a 50-day moving average price of $26.73 and a two-hundred day moving average price of $18.17. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). On average, equities research analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.